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Abstract
Background: Since soluble TRAIL exhibits anti-inflammatory and anti-atherosclerotic activities both in vitro and in animal
models, this study was designed to assess the relationship between the serum levels of TRAIL and clinical outcomes in
patients with acute myocardial infarction (AMI).
Methodology/Principal Findings: Levels of TRAIL were measured by ELISA in serial serum samples obtained from 60
patients admitted for AMI, both during hospitalization and in a follow-up of 12 months, as well as in 60 healthy control
subjects. Serum levels of TRAIL were significantly decreased in patients with AMI at baseline (within 24 hours from
admission), compared with healthy controls, and showed a significant inverse correlation with a series of negative
prognostic markers, such as CK, CK-MB and BNP. TRAIL serum levels progressively increased at discharge, but normalized
only at 6–12 months after AMI. Of note, low TRAIL levels at the patient discharge were associated with increased incidence
of cardiac death and heart failure in the 12-month follow-up, even after adjustment for demographic and clinical risk
parameters (hazard ratio [HR] of 0.93 [95% CI, 0.89 to 0.97]; p=0.001).
Conclusions/Significance: Although the number of patients studied was limited, our findings indicate for the first time that
circulating TRAIL might represent an important predictor of cardiovascular events, independent of conventional risk
markers.
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Introduction
Although in the serum of patients affected by acute myocardial
infarction (AMI) several cytokines, including those belonging to
the TNF family members, are known to be elevated [1], only
limited information is available on the role of TNF family
members in modulating cell death after myocardial ischemia [2–
4]. In this context, it has been suggested that the CD95 system
might be involved in post-ischemic cell death in the heart [2], and
it has been reported that the serum levels of TNF-related apoptosis
inducing ligand (TRAIL) tend to be reduced in patients with
coronary artery disease [5,6]. Although the cellular source of
serum TRAIL has not been clearly established, it is important to
point out that TRAIL is expressed as a type-II TNF family
transmembrane protein, but its extracellular domain can be
released as a soluble cytokine [7]. Interestingly, one study has
reported enhanced expression of transmembrane TRAIL on the
cell surface of circulating CD3
+ and CD14
+ cells after AMI and
has documented the expression of two of the four transmembrane
receptors for TRAIL, TRAIL-R1 and TRAIL-R2, in human
cardiomyocytes [3]. In this respect, however, it should be
mentioned that TRAIL-R1 and TRAIL-R2, which contain
cytoplasmic ‘‘death domains’’, not only mediate pro-apoptotic
signals but can also promote cell type-dependent pro-survival and
proliferation signals [8–12]. In particular, with regard to the
cardiovascular system, it has been shown that TRAIL can induce
apoptotic cell death of vascular endothelial cells only under certain
conditions, such as inhibition of the Akt pathway [13–20].
Whereas, under standard culture conditions, most of the available
studies have clearly demonstrated that recombinant soluble
TRAIL rather induces the activation of intracellular signaling
pathways, such as ERK/MAPK, Akt and NF-kB, which are
known to promote the survival/proliferation of endothelial and
vascular smooth muscle cells [8–20]. Furthermore, administration
of TRAIL significantly counteracted the development and
extension of atherosclerotic plaques in an experimental model of
atherosclerosis (apoE-null mice) [21].
In light of these experimental data, the aim of the present study
was to measure the serum levels of TRAIL in a cohort of AMI
patients, both at baseline (within 24 hours from AMI) and in the
follow-up (up to 12 months from AMI), and to assess the
relationship between TRAIL and short- and long-term incidence
of cardiovascular death and/or heart failure (HF). The selection of
this composite outcome was based on two independent consider-
ations: i) the same pathophysiological origin of both outcomes (i.e.,
death of cardiac origin and new-onset HF); ii) analyses by
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possible given small sample size, while the composite outcome has
allowed increasing the power to detect significant differences in
TRAIL levels between groups.
Methods
Patients, blood sampling and processing
The study population consisted of 60 AMI patients and 60
healthy control subjects. The AMI patients and the control group
did not significantly differ for age, sex and body mass index (BMI),
as evaluated by Student’s t test (for age and BMI) or chi-square test
(for percentage of men). Their demographic, clinical and
biochemical profiles are presented in Table 1. All participant
subjects gave written informed consent. The procedures followed
were in accordance with the Declaration of Helsinki and approved
by the institutional review board of the University Hospital of
Ferrara. Blood samples were collected from all AMI patients at
entry (1469 hours after symptom onset; range, 0.5 to 34 hours), at
the day of discharge, and 6 and 12 months after AMI. Blood
samples were left in ice for 45 minutes, and then centrifuged at
1700 g at 4uC for 15 minutes. Serum was aliquoted, stored at
280uC and thawed only once before analyses. The patients were
admitted to hospital for prolonged (.20 minutes) chest pain
accompanied by ST-segment changes of $1m mi n$1 peripheral
leads of the ECG or of $2m mi n$1 precordial leads. Exclusion
criteria were as follows: symptom onset .14 hours before hospital
admission, Killip class 4, history of HF, presence of any known
ongoing infectious disease, and any known current or past
neoplastic or immunological disorder. Occurrence of AMI was
confirmed in all patients by a 2-fold upper limit of normal (190 U/
L) rise in creatine kinase (CK), with an increased level of CK-MB.
None had clinical signs of acute or chronic illness or was receiving
any treatment. Patients were followed for 12 months for mortality
and morbidity end points. At discharge, medical treatment
consisted of nitrate (97%), ACE inhibitors (70%), b-blockers
(72%), statins (80%), thienopyridines (74%), diuretics (30%),
angiotensin II receptor blockers (18%). Dosages and timing of
drug administration were in accordance with current AHA/ACC
guidelines. None of the control group had clinical signs of acute or
chronic illness or was receiving any treatment.
Biochemical analyses
Serum TRAIL was measured in duplicate by specific,
commercially available ELISA kit (R&D Systems, Minneapolis,
MN) in accordance with the manufacturer’s instructions and
analyzed with an ELISA reader at 450 nm. Sensitivity of the assay
was 2.86 pg/ml and the intra- and inter-assay coefficients of
variation were 3.9% and 6%, respectively. Creatine kinase (CK)-
MB fraction in serum was measured on a modular platform
(Roche Diagnostics, Mannheim, Germany). The troponin I was
measured using an immunofluorescent assay calibrated with
spiked serum (Biosite Inc., San Diego, California). C-reactive
protein (CRP) was measured by nephelometry from fresh serum
according to the method of Behring Diagnostic. B-type natriuretic
peptide (BNP) was measured by commercial immunoradiometric
assay (Shonoria, Paris, France).
Follow-up and outcome measures
Patients underwent outpatient visits every 6 months. A
minimum follow-up of 12 months was planned. The main
outcome of interest was a hierarchical composite of total mortality
of cardiac origin and new-onset HF. All deaths were considered to
be of cardiac origin (n=9) unless a noncardiac origin (n=1) was
established clinically or at autopsy. Occurrence of HF, in
accordance with previously proposed criteria, required the
presence of rest or effort dyspnea and $1 of the following:
pulmonary rales at lung auscultation, S3 tone, evidence of
pulmonary congestion at chest X-ray, new appearance of
peripheral edema, or use of diuretics.
Statistical Analyses
Data are calculated and shown as mean6SD or as median and
Interquartile Range (IQR), according to the distribution. Differ-
ences in TRAIL mean values across study phases were analyzed
using analysis of variance (ANOVA) for repeated measures.
Comparisons between control subjects and patients, or between
patients with and without adverse clinical outcomes were
performed with chi-square test, Student’s t test or Wilcoxon test
for nonparametric variables. Correlations between TRAIL and
variables were estimated using Spearman’s correlation coefficient.
Survival among groups (above and below median TRAIL values
at discharge) was compared by use of the log-rank test, while a
Cox proportional-hazard model was used to calculate the crude
and adjusted risk estimates for the combined end point at
12 months of follow-up. In the multivariable analyses we adjusted
for potential confounders deemed to be clinically relevant,
including the following covariates: age, gender, diabetes, Killip
class (dichotomous, i.e., Killip class 1 vs. Killip class 2, 3), BMI,
CK, CK-MB and BNP. The most ‘‘parsimonuous’’ was selected
by mean of the Akaike Information Criterion (AIC), which
provides a measure of model quality by simulating the situation
where the model is tested on a different data set. The R software
(http://www.r-project.org/) was used for the analyses. A two-sided
p-value,0.05 has been chosen as statistically significant.
Results
TRAIL serum levels are markedly decreased in AMI
patients and tend to normalize only 6–12 months after
AMI
The demographic and biochemical characteristics of the study
populations analyzed for serum TRAIL levels are illustrated in
Table 1. At baseline, within 24 hours from admission, the AMI
patients showed significantly lower levels of serum TRAIL
Table 1. Charateristics of the study population.
Variables
Healthy Control
Subjects
AMI patients at
baseline
(n=60) (n=60)
Age (yrs) 58.4610.7 61.1611.9
Men (%) 78.3 83.3
BMI (kg/m
2)2 5 . 5 64.5 26.963.7
Diabetes (%) 0 22
Killip class .1 (%) …… 33.9
BNP (pg/ml) …… 110.8686.7
Peak CK-MB (ng/ml) …… 226.96234.2
Troponin I at peak (ng/ml) …… 113.46178,3
CRP (mg/dl) 0.860.3 3.766.8
CK (U/L) …… 2149.462022.4
Values given as percentage or mean6SD. BMI=body mass index; BNP=B-type
natriuretic peptide; CK=creatine kinase; CK-MB=creatine kinase-MB fraction;
CRP=C-reactive protein.
doi:10.1371/journal.pone.0004442.t001
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47.3 pg/ml (interquartile range 34.1 to 65 pg/ml) (Figure 1). In
the follow-up analysis of the same patients, we have observed a
progressive increase of the TRAIL levels. In particular, at
discharge (approximately 5–6 days after admission), the serum
levels of TRAIL were already significantly increased, compared to
the acute phase, but still significantly (p,0.01) lower with respect
to normal controls (Figure 1).
After six months post AMI, serum TRAIL levels were further
significantly increased, and no significant changes were observed
at later time points (12 months; Figure 1). Of note, the levels of
serum TRAIL measured in the group of patients 6–12 months
after AMI were not significantly different from those of healthy
control subjects (Figure 1).
TRAIL serum levels show an inverse correlation with
biochemical predictors of cardiovascular events
In the next group of analyses, the serum levels of TRAIL were
evaluated with respect to important biochemical markers of
cardiovascular related death and HF. We found an inverse
correlation between the serum levels of TRAIL, measured within
24 hours after admission, and both CK (R=20.48; p=0.002;
Figure 2A) and CK-MB (R=20.37; p=0.007; Figure 2B),
which represent important markers of degree of myocardial
damage immediately after AMI [22]. Moreover, an inverse
correlation was also observed between TRAIL and BNP
(R=20.47; p,0.001; Figure 2C), a well-known and important
prognostic marker of HF [23]. Of note, the association between
TRAIL and CK, CK-MB and BNP was significant, as evaluated
after multivariate regression adjusted for demographic and clinical
parameters (Tables 2–4). On the other hand, no significant
correlations were observed between TRAIL serum levels and
CRP, or TRAIL and troponin I (data not shown).
TRAIL serum levels are significantly lower in AMI patients
with primary outcomes with respect to AMI patients
without primary outcomes
Four patients died during hospitalization as a result of either
ventricle free wall rupture or refractory cardiogenic shock, while 7
patients developed new-onset heart failure (HF). It is noteworthy
that the TRAIL serum levels evaluated at baseline (within
24 hours) were significantly lower in the subgroup of patients
(18.3%) with in-hospital adverse clinical outcomes than in patients
without in-hospital cardiovascular events (p=0.01, Figure 3A).
The remaining 56 patients were next examined in a follow-up of
12–16 months. During this period, 6 patients died (5 of
cardiovascular causes), and 9 patients developed HF. In these 14
out of 56 patients (25%), TRAIL serum levels measured at
discharge were profoundly (p,0.01) reduced with respect to the
patient group without primary outcomes in the follow-up
(Figure 3B).
Decreased TRAIL serum levels represent a negative
prognostic factor at 12 months of follow-up in both
univariable and multivariable analyses
In next analysis, patients (n=56) were divided in two groups
based on the serum levels of TRAIL at discharge (below or above
median values) and the presence of primary outcomes between the
two groups in the follow-up was compared by use of the log-rank
test. A statistically significant difference (p,0.001) was observed in
terms of number of adverse outcomes in the follow-up, suggesting
Figure 1. Serum TRAIL levels in AMI patients and healthy individuals. Levels of TRAIL were determined by ELISA in sera from AMI patients
(analyzed at the indicated times post AMI) and from healthy control subjects. Horizontal bars are median, upper and lower edges of box are 75th and
25th percentiles, lines extending from box are 10th and 90th percentiles.
doi:10.1371/journal.pone.0004442.g001
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AMI represent a determinant of mortality and HF at 12 months of
follow-up in this study population. In Cox proportional-hazards
regression, after adjustment for potential confounders deemed to
be clinically relevant, such as age, gender, BMI, diabetes,
Killip.1, CK, CK-MB, and BNP, the TRAIL HR was 0.90
(95% CI, 0.83 to 0.98, p=0.014). Furthermore, even when Cox
proportional-hazards regression analysis was performed after AIC
selection, TRAIL still remained an independent and strong
predictor of mortality and cardiovascular events after AMI (HR
of 0.93, 95% CI, 0.89 to 0.97, p=0.001) (Table 5).
Discussion
In this pilot study, we have demonstrated that the serum levels
of TRAIL were significantly decreased in the early time points
after AMI (from admission until discharge) and progressively
increased in the follow-up (6–12 months later), reaching levels
comparable to those observed in the healthy controls. Our findings
Figure 2. Correlation between serum levels of TRAIL and negative prognostic markers. Inverse correlation between serum levels of TRAIL
and CK (A), between TRAIL and CK-MB (B) and between TRAIL and BNP (C) in AMI patients. Coefficients of correlation (R) are indicated.
doi:10.1371/journal.pone.0004442.g002
Table 2. Association between TRAIL and CK adjusted for
demographic and clinical parameters (multivariable linear
regression analysis).
Parameters Estimate Std. Error P
TRAIL (pg/ml) 20.016 0.007 0.019
Age (yrs) 20.013 0.012 0.249
Gender 0.196 0.356 0.584
BMI (kg/m
2) 0.047 0.037 0.201
UA 24.044 0.996 0.000
QWMI 20.956 0.295 0.002
Diabetes 20.297 0.330 0.372
BMI=body mass index; QWMI=Q-wave myocardial infarction; UA=unstable
angina.
doi:10.1371/journal.pone.0004442.t002
Table 3. Association between TRAIL and CK-MB adjusted for
demographic and clinical parameters (multivariable linear
regression analysis).
Parameters Estimate Std. Error P
TRAIL (pg/ml) 0.019 0.008 0.031
Age (yrs) 20.009 0.015 0.521
Gender 0.272 0.448 0.546
BMI (kg/m
2) 0.040 0.046 0.385
UA 25.964 1.256 0.000
QWMI 20.949 0.372 0.014
Diabetes 20.709 0.416 0.095
BMI=body mass index; QWMI=Q-wave myocardial infarction; UA=unstable
angina.
doi:10.1371/journal.pone.0004442.t003
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levels of TRAIL are decreased in patients affected by coronary
artery disease (including angina pectoris and AMI) [5,6]. While
these previous studies suggested that changes in the serum levels of
TRAIL might be related to the development of atherosclerotic
disease [5,6], as we have confirmed in a mouse model of
atherosclerosis [21], our present study is the first to provide
follow-up analysis of the TRAIL levels at various time points after
AMI and to indicate that the decreased serum levels of TRAIL
might have a negative prognostic significance in AMI patients.
Since both the cellular source of serum TRAIL and the
mechanisms of secretion of soluble TRAIL are incompletely
understood phenomena [7,24], it is unclear whether the significant
decline in the serum levels of TRAIL reflects a deficit of
production or an increased consumption of TRAIL in the acute
phase after AMI. With regard to the potential mechanisms of
consumption/clearance of TRAIL from the serum, several non-
mutually exclusive mechanisms may exist. For instance, it is
remarkable that metalloproteases have been reported to be
elevated in patients affected by AMI [25] and metalloproteases
are able to cleave and inactivate several cytokines/chemokines,
such as stromal cell derived factor-1 alpha [26]. Furthermore, it
has been previously demonstrated that metalloproteinase inhibi-
tors enhances the biological activity of soluble TRAIL [27]. For
these reasons we believe that it would be reasonable and of interest
to investigate whether also soluble TRAIL can be cleaved and/or
inactivated by metalloproteases.
The major finding of this study is the demonstration that the
decreased serum levels of TRAIL, measured within 24 hours after
AMI (baseline), were inversely correlated with important prognostic
markers for adverse cardiovascular events, such as circulating levels
Table 4. Association between TRAIL and BNP adjusted for
demographic and clinical parameters (multivariable linear
regression analysis).
Parameters Estimate Std. Error P
TRAIL (pg/ml) 20.033 0.008 0.000
Age (yrs) 0.032 0.013 0.013
Gender 0.109 0.388 0.780
BMI (kg/m
2) 20.015 0.039 0.707
UA 20.898 1.083 0.411
QWMI 0.048 0.322 0.883
Diabetes 20.363 0.353 0.309
BMI=body mass index; QWMI=Q-wave myocardial infarction; UA=unstable
angina.
doi:10.1371/journal.pone.0004442.t004
Figure 3. Serum TRAIL levels in AMI patient with respect to adverse clinical events. Serum levels of TRAIL were analyzed in AMI patient
who died or experienced HF (with events) either during the acute phase (in-hospital) or in the follow-up (12 months after AMI) with respect to the
other AMI patients (without events). Horizontal bars are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from
box are 10th and 90th percentiles.
doi:10.1371/journal.pone.0004442.g003
Table 5. Cox proportional-hazards regression tests for
predictors of death or new-onset HF after AIC selection.
Variables Analysis for Continuos Variables
HR (95% CI) p value
TRAIL (pg/ml) 0.93 (0.89–0.97) 0.001
Gender 0.14 (0.01–1.44) 0.098
CK 1.001 (1.000–1.001) 0.000
CI=confidence interval; CK=creatine kinase; HR=hazard ratio.
doi:10.1371/journal.pone.0004442.t005
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additional variables, deemed to be clinically relevant (i.e., age,
gender, BMI, diabetes, Killip.1) in a multivariate analysis, low
levels of TRAIL at discharge remained a significant predictor of
adverse cardiovascular in the follow-up of 12 months.
Although we are aware that a limitation of this exploratory
analysis is the relatively small sample size examined, which does
not allow to corroborate the prognostic relevance of TRAIL as a
biomarker, several possible mechanisms by which reduced TRAIL
serum/plasma levels might contribute to worsen the outcome of
AMI can be envisioned. For instance, in vitro studies have shown
that soluble recombinant TRAIL induces apoptotic cell death of
neutrophils [28,29]. Since neutrophils have been shown to play a
key role in worsening the necrosis post-AMI by releasing proteases
in the injured tissue [30,31], it is tempting to speculate that the
drastic decline in the serum levels of TRAIL after AMI might
induce a temporary impairment in the mechanisms of neutrophil
clearance after AMI. In addition, TRAIL exhibits endothelial
protective properties, which are related in part to nitric oxide
generation by endothelial cells themselves [16] and to an anti-
inflammatory activity [19]. An important confirmation that serum
TRAIL levels exert anti-inflammatory activity in clinically relevant
conditions comes from a recent study in which it has been
demonstrated that TRAIL levels progressively increase in the
serum of patients after allogenic stem cell transplantation and
show a protective effect against graft versus host disease and
endothelial cell damage [32].
In conclusion, the results of this pilot study demonstrate for the first
time that in AMI patients, in contrast to the raised serum levels of
inflammatory cytokines previously documented [1], serum levels of
TRAIL are profoundly down-regulated and might carry prognostic
information, independently of well-recognized outcome predictors.
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